Vyant Bio (NASDAQ: VYNT)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-15 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.160 | -0.150 | 0.0100 | ||||
REV | 300.000K | 303.000K | 3.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Vyant Bio (NASDAQ: VYNT) through any online brokerage.
Other companies in Vyant Bio’s space includes: Vincerx Pharma (NASDAQ:VINC), Cellectar Biosciences (NASDAQ:CLRB), Brooklyn (NASDAQ:BTX), Monopar Therapeutics (NASDAQ:MNPR) and T2 Biosystems (NASDAQ:TTOO).
The latest price target for Vyant Bio (NASDAQ: VYNT) was reported by HC Wainwright & Co. on Tuesday, May 17, 2022. The analyst firm set a price target for 3.00 expecting VYNT to rise to within 12 months (a possible 265.54% upside). 3 analyst firms have reported ratings in the last year.
The stock price for Vyant Bio (NASDAQ: VYNT) is $0.8207 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Vyant Bio.
Vyant Bio’s Q2 earnings are confirmed for Monday, August 15, 2022.
There is no upcoming split for Vyant Bio.
Vyant Bio is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.